It was also found that mitotane could potentially interfere with pituitary function by comparing adrenocorticotropic hormone (ACTH) levels between patients treated with mitotane for ACC and patients with primary adrenal insufficiency (autoimmune or post-adrenalectomy) [15]. This evidence concerns the gene POMC and adrenal cortex carcinoma.